Sildenafil Impact on Ventricular Function in Patients With Heart Failure
Sildenafil Impact on Ventricular Function in Patients With Heart Failure
Twenty-four patients with known heart failure will be recruited. They will undergo a cardiac
 magnetic resonance for ventricular analyses and after this first exam they will be randomized
 to placebo or Sildenafil. After one hour drug intake they will undergo another cardiac
 magnetic resonance to evaluate the drug impact on right and left ventricular function.
Twenty-four patients with known heart failure will be recruited. They will undergo a cardiac
 magnetic resonance for ventricular analyses and after this first exam they will be randomized
 to placebo or sildenafil. After one hour drug intake they will undergo another cardiac
 magnetic resonance to evaluate the drug impact on right and left ventricular function.

 The first and second exams will be performed by the same staff. All patients will be
 evaluated by two, three and four chambers view. Left and right ventricle quantification
 analyses will be performed by Argus software.
Inclusion Criteria: Patients with heart failure in stable clinical condition compatible
 with New York Heart Association functional class I to III. Eligibility criteria is consent
 to participate in the study after receiving detailed information about procedures, possible
 clinical benefits, and risks.

 Exclusion Criteria: patients with new diagnosed lesions during the procedure, eg pulmonary
 mass and important claustrophobia, low blood pressure ( systolic blood pressure <90 mmHg or
 diastolic blood pressure <60 mmHg) nitrate or nebivolol use over the last 48 hours,
 metallic non MRI compatible implantable devices.